De Cesaris R, Ranieri G, Filitti V, Andriani A, Bonfantino M V
Department of Biomedical Science and Human Oncology, University of Bari Medical School, Italy.
J Cardiovasc Pharmacol. 1993 Aug;22(2):208-14. doi: 10.1097/00005344-199308000-00006.
The aim of the study was to evaluate the efficacy of enalapril and atenolol in decreasing the severity of proteinuria in hypertensive patients suffering from insulin-dependent diabetes mellitus. We studied 20 hypertensive patients. All patients had proteinuria (> 3 g/24 h) and were receiving insulin treatment. Proteinuria was measured monthly in the run-in period (3 months) and during the active drug treatment (8 months). Glomerular filtration rate, effective renal plasma flow, filtration fraction, and total renal resistance were determined after the run-in and treatment periods. The patients were randomly assigned to treatment with enalapril 20 mg/day or atenolol 100 mg/day for 8 months. In both groups blood pressure decreased significantly. After 8 months' treatment, severity of proteinuria significantly decreased both in the enalapril-treated group and in the group receiving atenolol. Glomerular filtration rate and effective renal plasma flow significantly increased, while total renal resistance decreased in the patients given enalapril, whereas glomerular filtration rate, renal plasma flow, and total renal resistance significantly decreased in the patients given atenolol. The results of this study show that enalapril and atenolol reduce proteinuria in hypertensive diabetic patients by a mechanism related to their antihypertensive effects; furthermore, the beneficial effects of enalapril might be also linked to intrarenal effects.
本研究的目的是评估依那普利和阿替洛尔在降低胰岛素依赖型糖尿病高血压患者蛋白尿严重程度方面的疗效。我们研究了20例高血压患者。所有患者均有蛋白尿(>3g/24小时)且正在接受胰岛素治疗。在导入期(3个月)和活性药物治疗期(8个月)每月测量蛋白尿。在导入期和治疗期结束后测定肾小球滤过率、有效肾血浆流量、滤过分数和总肾阻力。患者被随机分配接受依那普利20mg/天或阿替洛尔100mg/天治疗8个月。两组血压均显著下降。治疗8个月后,依那普利治疗组和接受阿替洛尔治疗组的蛋白尿严重程度均显著降低。给予依那普利的患者肾小球滤过率和有效肾血浆流量显著增加,而总肾阻力降低,而给予阿替洛尔的患者肾小球滤过率、肾血浆流量和总肾阻力显著降低。本研究结果表明,依那普利和阿替洛尔通过与其降压作用相关的机制降低高血压糖尿病患者的蛋白尿;此外,依那普利的有益作用可能还与肾内作用有关。